# CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

> **NCT02336386** · PHASE3 · UNKNOWN · sponsor: **Beijing Chao Yang Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Extramedullary Plasmacytoma

## Interventions

- **DRUG:** CDD
- **DRUG:** CDD Plus Bortezomib

## Key facts

- **NCT ID:** NCT02336386
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336386, "CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02336386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*